Looking ahead on ACEL....When ACEL gets FDA approval, which IMO should be within a year, it should run to at least $40. Given contracts already in place they will have earnings of $2/share...at a PE of 30 the stock is between $40 and $60......To illustrate a recent comparison, in August, 2006 ACOR's stock price was $2. Two months later the stock price was $22. It rose to a high of roughly $27 in May, 2007 and is currently trading over $17.
What moved the stock price so dramatically from $2 to over $20 in the fall of 2006? On September 26, 2006 ACOR issued a press release reporting positive results of the Phase III trial of its drug candidate ... Fampridine-SR ... to improve walking capabilities in patients with MS. The PR news of positive Phase III trial results for this drug literally moved the stock price of ACOR from $2 to $20 in two months.
Unlike ACEL ... ACOR does not have "fast track" or " orphan drug " status with the FDA. ACOR is now conducting the Phase IIIB trial of the drug for any cardiovascular effects. This won't be completed until mid 2008. The FDA is not expected to rule on any NDA until sometime in 2009. Yet ACOR's stock rose from $2 to $20 in two months after the press release of positive Phase III results in September of 2006 ... and is still trading over $17 today. Barron's estimates that annual sales of the drug could approach $500 million/year within 5 years of any FDA approval. Barron's rates ACOR as a BUY at the current price ... as it moves toward a possible FDA decision in the next 2 years. The market for ONCONASE is substantially more lucrative and FDA approval for ACEL could be forthcoming much sooner.
The relevance of this summary above to ACEL is very important IMO in properly understanding ACEL's " Share Price Potential " from this point on. If ACOR"s stock can soar from $2 to $20 simply on the reporting and publicizing of positive Phase III trial results ... what can ACEL's stock price achieve if it properly announces and publicizes positive Phase IIIB trial results for ONCANASE?
